+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis



Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis



Neuroscience Letters 416(3): 257-260



A candidate neuroprotective agent for neurodegenerative disorders is erythropoietin (EPO). We measured EPO in cerebrospinal fluid (CSF) and serum of patients with amyotrophic lateral sclerosis (ALS). Patients with ALS (N=60), Alzheimer's disease (AD, N=20) and age-matched controls (N=33) were included. Patients with ALS included 30 patients who showed a rapid progression of disease, and 30 patients that showed a slower progression. EPO was measured using ELISA technique. We found CSF EPO levels to be lower in ALS as compared to AD and controls (p<0.05), while no differences were found with regard to serum levels. Patients with ALS who showed a rapid disease progression had lower CSF EPO levels compared to those who progressed more slowly (p=0.03). Low CSF EPO in ALS may imply that the EPO-associated capacity to protect neurons from degeneration is impaired in ALS. Low concentrations of CSF EPO seem to point towards a rapid progression of disease that may be associated with a poorer prognosis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013657740

Download citation: RISBibTeXText

PMID: 17368721

DOI: 10.1016/j.neulet.2007.02.002


Related references

Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neural Transmission 117(3): 343-347, 2010

Cerebrospinal fluid cytotoxicity in lateral amyotrophic sclerosis. Neurologia 25(6): 364-373, 2011

Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. Journal of Neurology 231(2): 75-78, 1984

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. European Journal of Neurology 6(5): 597-600, Sept, 1999

Cerebrospinal fluid proteins in the course of amyotrophic lateral sclerosis. Revue Neurologique 125(5): 393-400, 1971

Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochemical Research 33(11): 2358-2363, 2008

Cerebrospinal fluid oligocional proteins in amyotrophic lateral sclerosis. Archives of Neurology 36(2): 119, 1979

Cerebrospinal fluid amino acids in amyotrophic lateral sclerosis. Annals of Neurology 31(4): 449-450, 1992

Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Experimental and Therapeutic Medicine 11(6): 2095-2106, 2016

Amyotrophic lateral sclerosis: interleukin-6 levels in cerebrospinal fluid. Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques 19(3): 357-359, 1992

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Annals of Neurology 83(2): 258-268, 2018

Cerebrospinal Fluid Oligoclonal Proteins in Amyotrophic Lateral Sclerosis. Archives of Neurology 36(2): 119-119, 1979

Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. Journal of Neuroimmunology 225(1-2): 149-152, 2010

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. International Journal of Molecular Sciences 16(8): 17565-17588, 2016

Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis and sample size. Acta Neurologica Scandinavica 136(1): 79, 2017